{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:28Z","timestamp":1794047488177,"version":"4.8.0"},"reference-count":27,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The treatment landscape for hemophilia continues to rapidly develop, and expectations for future treatment success are high. There is limited information on the challenges of accessing new and innovative therapies. The aim of this study was to explore challenges of accessing hemophilia treatment from the perspective of healthcare professionals (HCP). A cross-sectional study design was used. A pilot-tested, online survey was distributed to hemophilia treatment centers in Australia, Canada, France, Italy, New Zealand, Republic of Ireland, Turkey, USA and UK. The questionnaire covered questions on product access, economic considerations, health technology assessment requirements, and patient organization involvement. The results were analyzed descriptively using SPSS. A total of 154 HCP completed the questionnaire. There was heterogeneity across countries, regions, and centers regarding HCP knowledge of access to novel recently developed treatments. Notable limitations to access were reported such as differences in access based on age of patient and type of product, economic considerations, and the growing influence of health technology assessment bodies. Many countries have a hemophilia patient organization that does not have a vote at the decision-making table. There is a need to empower HCP to better understand national healthcare structures and decisions that lead to access limitations. Requirements from health technology assessment bodies must be understood to optimally design clinical studies and value generation of treatment options. This may strengthen the hemophilia treatment center\u2019s voice to collectively mandate for exchange with key involved individuals, such as the payers and politicians for the provision of optimal therapy.<\/jats:p>","DOI":"10.3324\/haematol.2024.285647","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T03:41:07Z","timestamp":1731555667000},"page":"673-682","source":"Crossref","is-referenced-by-count":2,"title":["Challenges associated with access to recently developed hemophilia treatments in routine care: perspectives of healthcare professionals"],"prefix":"10.3324","volume":"110","author":[{"given":"Karin","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxy H.","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo Nicola Dario","family":"Di Minno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Batorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaan","family":"Kavakli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Mannuccio","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda L.","family":"Bohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Aledort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"73224","doi-asserted-by":"crossref","unstructured":"Stonebraker JS, Bolton\u2010Maggs PH, Brooker M. The World Federation of Hemophilia annual global survey 1999\u20102018. Haemophilia. 2020; 26(4):591-600.","DOI":"10.1111\/hae.14012"},{"key":"73225","doi-asserted-by":"crossref","unstructured":"Elsafy OR, Mohammed MA, Abdelfatah NR, Ishtaiwi IE. Impact of hemophilia on health-related quality of life in pediatric population. Egypt J Hosp Med. 2021; 85(1):3047-3412.","DOI":"10.21608\/ejhm.2021.199590"},{"key":"73226","doi-asserted-by":"crossref","unstructured":"von Mackensen S, Gringeri A. Quality of life in hemophilia. John Wiley & Sons, Ltd. 2014;478-488.","DOI":"10.1002\/9781118398258.ch64"},{"key":"73227","doi-asserted-by":"crossref","unstructured":"Berntorp E, Hermans C, Solms A, Poulsen L, Mancuso ME. Optimising prophylaxis in haemophilia A: the ups and downs of treatment. Blood Rev. 2021; 50:100852.","DOI":"10.1016\/j.blre.2021.100852"},{"key":"73228","doi-asserted-by":"crossref","unstructured":"Mannucci PM. Hemophilia treatment innovation: 50 years of progress and more to come. J Thromb Haemost. 2023; 21(3):403-412.","DOI":"10.1016\/j.jtha.2022.12.029"},{"key":"73229","doi-asserted-by":"crossref","unstructured":"Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016; 388(10040):187-197.","DOI":"10.1016\/S0140-6736(15)01123-X"},{"key":"73230","doi-asserted-by":"crossref","unstructured":"Weyand AC, Pipe SW. New therapies for hemophilia. Blood. 2019; 133(5):389-398.","DOI":"10.1182\/blood-2018-08-872291"},{"key":"73231","doi-asserted-by":"crossref","unstructured":"Gogia P, Tarantino M, Schramm W, Aledort L. New directions to develop therapies for people with hemophilia. Expert Rev Hematol. 2023; 16(6):417-433.","DOI":"10.1080\/17474086.2023.2184341"},{"key":"73232","doi-asserted-by":"crossref","unstructured":"Ghosh K, Ghosh K. Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence. Expert Rev Hematol. 2021; 14(8):721-730.","DOI":"10.1080\/17474086.2021.1957826"},{"key":"73233","doi-asserted-by":"crossref","unstructured":"Pelland-Marcotte MC, Carcao MD. Hemophilia in a changing treatment landscape. Hematol Oncol Clin North Am. 2019; 33(3):409-423.","DOI":"10.1016\/j.hoc.2019.01.007"},{"key":"73234","doi-asserted-by":"crossref","unstructured":"Rodriguez-Merchan EC. The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality. Expert Rev Hematol. 2020; 13(3):269-274.","DOI":"10.1080\/17474086.2020.1716726"},{"key":"73235","doi-asserted-by":"crossref","unstructured":"Ghosh K, Ghosh K. Management of haemophilia in developing countries: challenges and options. Indian J Hematol Blood Transfus. 2016; 32(3):347-355.","DOI":"10.1007\/s12288-015-0562-x"},{"key":"73236","doi-asserted-by":"crossref","unstructured":"Ten Ham RM, Walker SM, Soares MO. Modeling benefits, costs, and affordability of a novel gene therapy in hemophilia A. Hemasphere. 2022; 6(2):e679.","DOI":"10.1097\/HS9.0000000000000679"},{"key":"73237","doi-asserted-by":"crossref","unstructured":"Thorat T, Neumann PJ, Chambers JD. Hemophilia burden of disease: a systematic review of the cost-utility literature for hemophilia. J Manag Care Spec Pharm. 2018; 24(7):632-642.","DOI":"10.18553\/jmcp.2018.24.7.632"},{"key":"73238","doi-asserted-by":"crossref","unstructured":"O\u2019Mahony B, Wong O, Eichler H, Neumann P, Carlsson KS, Noone D. Preparing for tomorrow: defining a future agenda. Haemophilia. 2022; 28(Suppl 2):35-41.","DOI":"10.1111\/hae.14476"},{"key":"73239","doi-asserted-by":"crossref","unstructured":"O\u2019Hara J, Neumann PJ, International Haemophilia Access Strategy Council. Health technology assessment for gene therapies in haemophilia. Haemophilia. 2022; 28(Suppl 2):19-26.","DOI":"10.1111\/hae.14413"},{"key":"73240","doi-asserted-by":"crossref","unstructured":"Skinner MW, Dolan G, Eichler H, O\u2019Mahony B, International Haemophilia Access Strategy Council. A preliminary application of a haemophilia value framework to emerging therapies in haemophilia. Haemophilia. 2022; 28(Suppl 2):9-18.","DOI":"10.1111\/hae.14511"},{"key":"73241","doi-asserted-by":"crossref","unstructured":"Berger K, Batarova A, Bohn R. Are all licensed haemostatic agents for haemophilia therapy accessible to patients?. Haemophilia. 2022; 28(6):e256-e258.","DOI":"10.1111\/hae.14660"},{"key":"73242","doi-asserted-by":"crossref","unstructured":"Meyer VM, Benjamens S, El Moumni M, Lange JF, Pol RA. Global overview of response rates in patient and health care professional surveys in surgery: a systematic review. Ann Surg. 2022; 275(1):e75-e81.","DOI":"10.1097\/SLA.0000000000004078"},{"key":"73243","doi-asserted-by":"crossref","unstructured":"Cunningham CT, Quan H, Hemmelgarn B. Exploring physician specialist response rates to web-based surveys. BMC Med Res Methodol. 2015; 15:32.","DOI":"10.1186\/s12874-015-0016-z"},{"key":"73244","doi-asserted-by":"crossref","unstructured":"Wu MJ, Zhao K, Fils-Aime F. Response rates of online surveys in published research: a meta-analysis. Comput Hum Behav Rep. 2022; 7:100206.","DOI":"10.1016\/j.chbr.2022.100206"},{"key":"73245","doi-asserted-by":"crossref","unstructured":"Eysenbach G. Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J Med Int Res. 2004; 6(3):e34.","DOI":"10.2196\/jmir.6.3.e34"},{"key":"73246","doi-asserted-by":"crossref","unstructured":"Peyvandi F, Berger K, Seitz R. Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies. Haematologica. 2020; 105(8):2038-2043.","DOI":"10.3324\/haematol.2019.242735"},{"key":"73247","doi-asserted-by":"crossref","unstructured":"Krause SW, Schildmann J, Lotze C, Winkler EC. Rationing cancer care: a survey among the members of the German Society of Hematology and Oncology. J Natl Compr Canc Netw. 2013; 11(6):658-665.","DOI":"10.6004\/jnccn.2013.0085"},{"key":"73248","doi-asserted-by":"crossref","unstructured":"Moosa MR, Luyckx VA. The realities of rationing in health care. Nat Rev Nephrol. 2021; 17(7):435-436.","DOI":"10.1038\/s41581-021-00404-8"},{"key":"73249","doi-asserted-by":"crossref","unstructured":"Mikami K, Sturdy S. Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop. Res Involv Engagem. 2017; 3:14.","DOI":"10.1186\/s40900-017-0065-z"},{"key":"73250","unstructured":"Metreau E, Young KE, Eapen SG. World Bank country classifications by income level for 2024-2025. World Bank Blogs. 2024."}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11818\/77755","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11818\/78109","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11818\/77755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:37Z","timestamp":1794046057000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285647","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,14]]}}}